Tenaya Therapeutics Inc (TNYA)

Currency in USD
0.757
+0.076(+11.16%)
Closed·
0.760+0.003(+0.37%)
·
TNYA Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
TNYA is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
0.6700.759
52 wk Range
0.3604.010
Key Statistics
Prev. Close
0.757
Open
0.68
Day's Range
0.67-0.759
52 wk Range
0.36-4.01
Volume
2.49M
Average Volume (3m)
2.41M
1-Year Change
-72.17%
Book Value / Share
0.61
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
TNYA Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
10.143
Upside
+1,239.88%
Members' Sentiments
Bearish
Bullish
ProTips
6 analysts have revised their earnings upwards for the upcoming period

Tenaya Therapeutics Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy

Tenaya Therapeutics Inc Company Profile

Tenaya Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. The company’s lead product candidate includes TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy that is in phase 2 clinical trial; TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy, which is in phase 1 clinical trial; and TN-301, a small molecule histone deacetylase-6 for heart failure with preserved ejection fraction that is in phase 1 clinical trial. It also develops an adeno-associated virus-based gene therapy designed to deliver the dworf gene for patient with dilated cardiomyopathy; and reprogramming program for heart failure due to prior myocardial infarction. The company develops its products through gene editing, cellular regeneration, gene silencing, and gene addition. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

Tenaya Therapeutics Inc SWOT Analysis


Pivotal Gene Therapy
Tenaya Therapeutics approaches critical milestones in cardiac gene therapy development, with key clinical trial data expected in late 2024
AAV9 Vector Promise
Explore Tenaya's innovative use of AAV9 delivery vector, showing superior performance across species and potential for enhanced efficacy in humans
Market Positioning
Delve into Tenaya's strategic focus on MYBPC3-related hypertrophic cardiomyopathy, addressing a significant unmet need in cardiac genetic disorders
Financial Outlook
Analyst price target of $40 highlights potential upside, with stock performance closely tied to upcoming clinical trial outcomes and cash management
Read full SWOT analysis

Compare TNYA to Peers and Sector

Metrics to compare
TNYA
Peers
Sector
Relationship
P/E Ratio
−1.2x−2.4x−0.5x
PEG Ratio
−0.03−0.100.00
Price/Book
1.2x1.7x2.6x
Price / LTM Sales
-8.7x3.3x
Upside (Analyst Target)
-311.5%41.6%
Fair Value Upside
Unlock17.9%5.9%Unlock

Analyst Ratings

8 Buy
0 Hold
0 Sell
Ratings:
8 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 10.143
(+1,239.88% Upside)

Earnings

Latest Release
Aug 06, 2025
EPS / Forecast
-0.14 / -0.18
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

TNYA Income Statement

People Also Watch

18.80
SRPT
+4.79%
1.660
VOR
-16.58%
62.44
BMNR
+5.87%
4.130
ATAI
+4.29%

FAQ

What Stock Exchange Does Tenaya Therapeutics Trade On?

Tenaya Therapeutics is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Tenaya Therapeutics?

The stock symbol for Tenaya Therapeutics is "TNYA."

What Is the Tenaya Therapeutics Market Cap?

As of today, Tenaya Therapeutics market cap is 123.37M.

What Is Tenaya Therapeutics's Earnings Per Share (TTM)?

The Tenaya Therapeutics EPS (TTM) is -0.89.

When Is the Next Tenaya Therapeutics Earnings Date?

Tenaya Therapeutics will release its next earnings report on 04 Nov 2025.

From a Technical Analysis Perspective, Is TNYA a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Tenaya Therapeutics Stock Split?

Tenaya Therapeutics has split 0 times.

How Many Employees Does Tenaya Therapeutics Have?

Tenaya Therapeutics has 97 employees.

What is the current trading status of Tenaya Therapeutics (TNYA)?

As of 13 Aug 2025, Tenaya Therapeutics (TNYA) is trading at a price of 0.76, with a previous close of 0.76. The stock has fluctuated within a day range of 0.67 to 0.76, while its 52-week range spans from 0.36 to 4.01.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.